Spelling suggestions: "subject:"bonemarrow"" "subject:"marrow""
761 |
Development of cellular and gene therapies for b[beta]-Thalassemia and sickle cell diseaseFelfly, Hady January 2008 (has links)
Thèse numérisée par la Division de la gestion de documents et des archives de l'Université de Montréal
|
762 |
Gene expression of tendon markers in mesenchymal stromal cells derived from different sourcesBurk, Janina, Gittel, Claudia, Heller, Sandra, Pfeiffer, Bastian, Paebst, Felicitas, Ahrberg, Annette B., Brehm, Walter 15 December 2014 (has links) (PDF)
Background: Multipotent mesenchymal stromal cells (MSC) can be recovered from a variety of tissues in the body. Yet, their functional properties were shown to vary depending on tissue origin. While MSC have emerged as a favoured cell type for tendon regenerative therapies, very little is known about the influence of the MSC source on
their properties relevant to tendon regeneration. The aim of this study was to assess and compare the expression of tendon extracellular matrix proteins and tendon differentiation markers in MSC derived from different sources as well as in native tendon tissue. MSC isolated from equine bone marrow, adipose tissue, umbilical cord tissue, umbilical cord blood and tendon tissue were characterized and then subjected to mRNA analysis by real-time polymerase chain reaction. Results: MSC derived from adipose tissue displayed the highest expression of collagen 1A2, collagen 3A1 and decorin compared to MSC from all other sources and native tendon tissue (p < 0.01). Tenascin-C and scleraxis
expressions were highest in MSC derived from cord blood compared to MSC derived from other sources, though both tenascin-C and scleraxis were expressed at significantly lower levels in all MSC compared to native tendon tissue (p < 0.01). Conclusions: These findings demonstrate that the MSC source impacts the cell properties relevant to tendon regeneration. Adipose derived MSC might be superior regarding their potential to positively influence tendon matrix reorganization.
|
763 |
Characterization of bone marrow stromal clonal populations derived from osteoarthritis patientsMareddy, Shobha R. January 2008 (has links)
This work is concerned with the characterization of mesenchymal stem cells (MSC) specifically from bone marrow samples derived from patients with osteoarthritis (OA). The multilineage potential of mesenchymal stem cells as well as their ease of exvivo expansion makes these cells an attractive therapeutic tool for applications such as autologous transplantation and tissue engineering. Bone marrow is considered a source of MSC. However, there is a general assumption that the occurrence of MSCs and their activity in bone marrow diminishes with age and disease. This prompted us to isolate and identify multipotential and self-renewing cells from patients with the degenerative disease osteoarthritis, with the view of using these cells for autologous cell therapies. It is therefore of great potential benefit to investigate the isolation and characterization of stem cell/progenitors from bone marrow samples of patients with osteoarthritis in greater detail. We employed a single cell clone culture method in order to develop clonal cell populations from three bone marrow samples and characterized them based on their proliferation and differentiation capabilities. The clonal populations were grouped into fast-growing and slow-growing clones based on their proliferation rates. The fastgrowing clones displayed 20-30% greater proliferation rate than the slow-growing clones. The study also revealed that the proliferation rates were directly proportional to their differentiation capacities. Most of the fast-growing clones were found to be tripotential for osteogenic, chondrogenic and adipogenic lineages, whereas the slow growing clones were either uni or bipotential. Flow cytometry analysis for the phenotype determination using putative MSC surface markers did not reveal any difference between the two clonal populations indicating a need for further molecular studies. Two approaches were employed to further investigate the molecular processes involved in the existence of such varying populations. In the first method gene expression studies were performed between the fast-growing (n=3) and slow-growing (n=3) clonal populations to identify potential genetic markers associated with cell 'sternness' using the Stem Cell RT2 ProfilerTM PCR Array comprising a series of 84 genes related to stem cell pathways. Ten genes were identified to be commonly and significantly over represented in the fast-growing stem cell clones when compared to slow-growing clones. This included expression of transcripts beyond MSC lineage specification such as SOX2, NOTCH1 and FOXA2 which signified that stem cell maintenance requires a coordinated regulation by multiple signalling pathways. The second study involved an extensive protein expression profiling of the fast growing (n=2) and slow growing (n=2) clonal populations using off-line Two Dimensional Liquid Chromatography (2D-LC)/Matrix-Assisted Laser Desorption/Ionization (MALDI) Mass Spectrometry (MS). A total of 67 proteins were identified, of which 11 were expressed at significantly different levels between the subpopulations. Protein ontology revealed these proteins to be associated with cellular organization, cytokinesis, signal transduction, energy pathways and cell stress response. Of particular interest was the differential presentation of the proteins calmodulin, tropomyosin and caldesmon between fast- and slow-growing clones. Based on their reported roles in the regulation of cell proliferation and maintenance of cell integrity, we draw an association between their expression and the altered status in which the subpopulations exist. Based on our observations, these proteins may be prospective molecular markers to distinguish between the fast-growing and slow-growing subpopulations. In summary, this study demonstrated the existence of potential stem cells of therapeutic importance in spite of a supposedly smaller stem cell compartment in patients with osteoarthritis. Furthermore, the differentially expressed genes between the sub-populations highlight the 'sternness' of the potential clones, an observation supported by the expression of proteins which act as effective modulators in the maintenance of cell integrity and cell cycle regulation. This study provides a basis for more detailed investigations in search of selective cell surface markers
|
764 |
STAT3 contributes to resistance towards BCR-ABL inhibitors in a bone marrow microenvironment model of drug resistance in chronic myeloid leukemia cells /Bewry, Nadine N. January 2009 (has links)
Dissertation (Ph.D.)--University of South Florida, 2009. / Includes vita. Includes bibliographical references. Also available online.
|
765 |
STAT3 contributes to resistance towards BCR-ABL inhibitors in a bone marrow microenvironment model of drug resistance in chronic myeloid leukemia cellsBewry, Nadine N. January 2009 (has links)
Dissertation (Ph.D.)--University of South Florida, 2009. / Title from PDF of title page. Document formatted into pages; contains 149 pages. Includes vita. Includes bibliographical references.
|
766 |
Quantificação das células estreladas ativadas / miofibroblastos e análise da apoptose das células do fígado durante a terapia celular na fibrose hepática em ratos / Quantification of actived stellate cells / myofibroblasts and analysis of apoptosis of liver cells during cell therapy in liver fibrosis in ratsDalvaci da Cunha Lira Neves 27 July 2011 (has links)
Coordenação de Aperfeiçoamento de Pessoal de Nível Superior / A fibrose hepática é o resultado de uma resposta cicatrizante frente a repetidas lesões no fígado, e é caracterizada pelo acúmulo excessivo de proteínas da matriz extracelular (MEC) no parênquima hepático, incluindo colágeno, fibronectina, elastina, laminina e proteoglicanos, com a participação de diferentes populações celulares do fígado. As principais células responsáveis pela síntese de proteínas da MEC na fibrose hepática são as células estreladas hepáticas ativadas e os miofibroblastos, que surgem após estímulo inflamatório e são caracterizadas pela expressão de alfa-actina de músculo liso (α-SMA). Sabe-se que durante a progressão da fibrose hepática, ocorre a morte de hepatócitos e sua substituição por células fibrogênicas α-SMA+. A apoptose dessas células fibrogênicas é de grande relevância para a regressão da fibrose e regeneração hepática. Nos últimos anos, a terapia com células tronco de medula óssea tem sido utilizada para estimular a regeneração hepática em diferentes modelos experimentais e protocolos clínicos. A fração mononuclear da medula óssea adulta possui duas populações de células-tronco importantes no tratamento de diversas doenças hepáticas: células-tronco hematopoiéticas e células-tronco mesenquimais. O objetivo deste estudo foi analisar a expressão de α-SMA e o processo de apoptose de células hepáticas durante a fibrose hepática induzida por ligadura do ducto biliar (LDB) e após o transplante de células mononucleares de medula óssea (CMMO). Os fígados foram coletados de ratos dos seguintes grupos: normal, 14 dias de LDB, 21 dias de LDB e animais que receberam CMMO após 14 dias de LDB, e foram analisados após 7 dias (totalizando 21 dias de LDB). Para quantificar a expressão de α-SMA por células fibrogênicas nos grupos experimentais, foi realizada imunoperoxidase para α-SMA, seguida de morfometria no programa Image Pro Plus. Para analisar a apoptose nas células hepáticas, foi realizada imunoperoxidase e Western Blotting (WB) para caspase-3 (proteína apoptótica) e imunofluorescência com dupla-marcação para caspase-3 e α-SMA, seguida de observação em microscópio confocal. Os resultados da quantificação de α-SMA por morfometria mostraram que a expressão de α-SMA aumentou significativamente 14 e 21 dias após a LDB. Entretanto, essa expressão diminuiu significativamente no grupo tratado com CMMO, que apresentou parênquima hepático mais preservado em relação ao grupo com 21 dias de LDB. Os resultados de imunoperoxidase, WB e microscopia confocal para expressão de caspase-3 demonstraram que essa proteína diminuiu nos animais fibróticos com 14 e 21 dias de LDB com relação ao grupo normal, e estava significativamente elevada no grupo tratado com CMMO. A análise por microscopia confocal demonstrou que algumas células coexpressaram α-SMA e caspase-3 nos animais tratados com CMMO, sugerindo a morte de células fibrogênicas e remodelamento do parênquima hepático. / Hepatic fibrosis is the result of a scarring response due to continued injury to the liver, and is featured by excessive accumulation of extracellular matrix (MEC) proteins in hepatic parenchyma. These proteins include collagen, fibronectin, elastin, laminin and proteoglicans, along with the participation of different cell populations within the liver. The main cells responsible for the synthesis of MEC proteins are activated hepatic stellate cells and myofibroblasts, which appear after inflammatory stimuli and are characterized by the expression of alpha-smooth muscle actin (α-SMA). It is known that hepatic fibrosis progression is accompanied by hepatocyte death and its substitution by α-SMA+ fibrogenic cells. Therefore, apoptosis of these fibrogenic cells is of main relevance to fibrosis regression and hepatic regeneration. In the later years, bone marrow stem cell therapy has been used to stimulate hepatic regeneration in different experimental models and clinical protocols. The adult bone marrow mononuclear fraction contains two stem cell populations particularly important in the treatment of diverse hepatic diseases: hematopoietic stem cells and mesenchymal stem cells. The aim of this study was to analyze α-SMA expression and the apoptotic process in hepatic cells during hepatic fibrosis induced by bile duct ligation (BDL) and after bone marrow mononuclear cell (BMMC) transplantation. Livers were collect from rats of the following groups: normal, 14 days of BDL, 21 days of BDL and rats that received BMMC 14 days after BDL and were analyzed after 7 days (total of 21 days of BDL). To quantify α-SMA expression by fibrogenic cells in the experimental groups, immunoperoxidase to α-SMA followed by morphometry in the Image Pro Plus software was performed. To analyze apoptosis in hepatic cells, immunoperoxidase and western blotting (WB) against caspase-3 (apoptotic protein) were used, along with double immunofluorescence against caspase-3 and α-SMA to confocal microscopy analysis. Results of α-SMA quantification by morphometry showed that α-SMA expression increased significantly 14 and 21 days after BDL. However, this expression was significantly decreased in the BMMC treated group, which presented a more preserved hepatic parenchyma in relation to the group with 21 days of BDL. Immunoperoxidase, WB and confocal microscopy results showed that caspase-3 is decreased in fibrotic livers with 14 and 21 days of BDL in comparison to normal group, and was significantly augmented in the BMMC treated group. Confocal microscopy analysis showed that were cells coexpressing α-SMA and caspase-3 in rats treated with BMMC, suggesting fibrogenic cells death and hepatic remodeling.
|
767 |
Les immunoglobulines intraveineuses et la réponse spécifique des cellules T dans la prévention de la maladie lymphoproliférative post-greffe associée au virus Epstein-Barr chez les enfants greffés de cellules souches hématopoïétiquesBah, Ramatoulaye 01 1900 (has links)
No description available.
|
768 |
Protocolo para avaliação e terapia nutricional no transplante de células hematopoiéticas em pacientes do Hospital das Clínicas de Botucatu / Evaluation and nutritional therapy protocol for patients in hematopoietic stem cell transplantation program in Hospital das Clínicas de BotucatuCosta, Cesar Martins da 02 May 2018 (has links)
Submitted by Cesar Martins da Costa (cesarmt_costa@hotmail.com) on 2018-08-29T01:13:06Z
No. of bitstreams: 1
Repositório 28_08_18(3).pdf: 1899213 bytes, checksum: 4d06edd1c8c52ada7f2c1e6877ca335e (MD5) / Rejected by ROSANGELA APARECIDA LOBO null (rosangelalobo@btu.unesp.br), reason: Solicitamos que realize uma nova submissão seguindo as orientações abaixo:
problema 1: Capa
No arquivo submetido faltou a capa, item obrigatório de acordo com as normas do seu programa de pós.
problema 2: ficha catalográfica
No arquivo submetido não consta a ficha catalográfica, item obrigatório para submissão. A ficha deve ser incluída no arquivo PDF logo após a folha de rosto do seu trabalho.
Assim que tiver efetuado a correção submeta o arquivo em PDF novamente
Agradecemos a compreensão. on 2018-08-31T14:00:19Z (GMT) / Submitted by Cesar Martins da Costa (cesarmt_costa@hotmail.com) on 2018-09-02T20:04:42Z
No. of bitstreams: 1
Repositório_02_09.pdf: 1813055 bytes, checksum: 28ed24672d32c464e368529cae5993bc (MD5) / Rejected by Sulamita Selma C Colnago null (sulamita@btu.unesp.br), reason: Solicitamos que realize uma nova submissão seguindo as orientações abaixo:
Problema 1: A capa do seu trabalho não está de acordo com as normas do Programa de Pós-Graduação.
Assim que efetuar essa(s) correção(ões), submeta o arquivo em PDF novamente.
Agradecemos a compreensão.
on 2018-09-03T17:01:07Z (GMT) / Submitted by Cesar Martins da Costa (cesarmt_costa@hotmail.com) on 2018-09-04T02:44:43Z
No. of bitstreams: 1
Repositório_03_09.pdf: 1792756 bytes, checksum: 66827eabf8f9f93bf0427b25dd02e0e2 (MD5) / Approved for entry into archive by ROSANGELA APARECIDA LOBO null (rosangelalobo@btu.unesp.br) on 2018-09-04T19:18:59Z (GMT) No. of bitstreams: 1
costa_cm_me_bot.pdf: 1792756 bytes, checksum: 66827eabf8f9f93bf0427b25dd02e0e2 (MD5) / Made available in DSpace on 2018-09-04T19:18:59Z (GMT). No. of bitstreams: 1
costa_cm_me_bot.pdf: 1792756 bytes, checksum: 66827eabf8f9f93bf0427b25dd02e0e2 (MD5)
Previous issue date: 2018-05-02 / O Transplante de Células Progenitoras Hematopoiéticas (TCPH) é um método terapêutico utilizado no tratamento de diversas doenças que envolvem o tecido linfo-hematopoiético, doenças autoimunes e condições não-malignas. As evidências apontam que o reconhecimento precoce de pacientes em grupos de risco nutricional no TCPH e a elaboração de um plano terapêutico para tal tem impacto positivo na redução da mortalidade. A monitorização diária das necessidades energéticas, proteicas e de nutrientes é um dos pontos cruciais da terapia, pois o paciente que é incapaz de suprir mais do que 60% das necessidades nutricionais diárias por via oral torna-se candidato a outras modalidades de terapia (enteral ou parenteral), a depender da viabilidade do trato gastrointestinal, das contra-indicações relativas a cada método (plaquetopenia na introdução de sonda nasoenteral, por exemplo) e das complicações associadas aos procedimentos (aumento das taxas de infecção de corrente sanguínea na nutrição parenteral). Se o paciente atingir mais do que 60% das necessidades nutricionais por via oral e mantiver esse aporte por pelo menos 3 dias, o suporte por nutrição enteral ou parenteral pode ser descontinuado. A literatura científica ainda não elucidou todos os questionamentos quanto à melhor abordagem nutricional em pacientes submetidos a TCPH, podendo-se observar grande variação entre as condutas orientadas pelas diretrizes internacionais mais recentes e o que se adota como prática clínica diária, chamando atenção para a necessidade da elaboração de protocolos nutricionais que diminuam essas divergências. Objetivos: elaboração de um manual de avaliação do risco nutricional e de implementação de terapia nutricional para pacientes que serão submetidos ao Transplante de Células Progenitoras Hematopoiéticas no Hospital das Clínicas de Botucatu, facilitando a tomada de decisões de acordo com as evidências científicas mais recentes e contribuindo para minimizar as divergências de condutas através de um protocolo nutricional hospitalar. Casuística e Métodos: o manual foi elaborado por meio de uma revisão narrativa da literatura científica, utilizando-se de artigos e diretrizes relevantes contidos nas bases de dados Pubmed, Lilacs e Scielo, assim como de livros textos e de consensos desde o ano 2000 até 2017. Para a busca, os termos utilizados foram “nutrition assessment", "nutrition therapy", "nutrition risk", “undernutrition”, "malnutrition", “obesity”, "chemotherapy", “blood 8 marrow transplantation”, “haematopoietic stem cell transplantation”, “body composition”, “phase angle”. Resultados: há escassez de estudos específicos relacionados a terapia nutricional e a TCPH. A busca resultou na utilização de 20 trabalhos científicos que embasam a produção desta dissertação. Considerando a estrutura e a dinâmica do Hospital das Clínicas de Botucatu, a padronização de condutas deste Manual levou à elaboração de um protocolo em forma de fluxograma que abrange a avaliação do Risco Nutricional e de aplicação da Terapia Nutricional em pacientes submetidos ao TCPH neste serviço de saúde. Conclusão: o protocolo de avaliação de Risco e de aplicação de Terapia Nutricional, redigido em forma de fluxograma, facilita a aplicabilidade do conteúdo do Manual para os profissionais que dele se utilizarão, simplifica a classificação dos grupos de risco nutricional, disponibiliza elaboração rápida de condutas e evita divergências de prescrição quanto à melhor Terapia Nutricional em pacientes submetidos ao TCPH. / Hematopoietic Stem Cell Transplantation (HSCT) is a therapeutic method used for treatment of various diseases involving lymphohematopoietic tissue, autoimmune diseases and non-malignant conditions. Evidence indicates that the early recognition of nutritional risk in HSCT patients and the elaboration of a therapeutic plan for them has a positive impact in reducing mortality. Monitoring daily needs of energy, protein and nutrient is one of the crucial points of therapy, because individuals who are unable to supply more than 60% of the daily nutritional needs orally become candidates for other modalities of therapy (enteral or parenteral), depending on the viability of the gastrointestinal tract, contraindications for each method (thrombocytopenia in the introduction of nasoenteral probe, for example) and complications associated with procedures (increased bloodstream infection rates in parenteral nutrition) . If the patient reaches more than 60% of nutritional needs orally and maintains this intake for at least 3 days, enteral or parenteral nutrition support may be discontinued. The scientific literature has not yet elucidated all the questions regarding the best nutritional approach in patients undergoing HSCT and a great variation between the conducts guided by the most recent international guidelines and what is adopted as daily clinical practice can be observed, drawing attention to the need for nutritional protocols that could reduce these divergences. Objectives: elaboration of a manual of nutritional therapy and nutritional risk assessment for patients in the Hematopoietic Progenitor Cell Transplantation program at the Hospital das Clínicas de Botucatu, facilitating decision-making according to the latest scientific evidence and contributing to minimize differences of conduct guided by a hospital nutritional protocol. Materials and Methods: the manual is a narrative review of the scientific literature, using relevant articles and guidelines contained in the Pubmed, Lilacs and Scielo databases, as well as textbooks and consensus books from year 2000 to 2017. The terms used for the research were “nutrition assessment”, “nutrition therapy”, “nutrition risk”, “undernutrition”, “malnutrition”, “obesity”, “chemotherapy”, “blood marrow transplantation”, “haematopoietic stem cell transplantation","Body composition","phase angle". Results: there are few specific studies related to nutritional therapy and HSCT. The search resulted in the use of 20 scientific papers that support the production of this dissertation. Considering the structure and dynamics of Hospital das Clínicas de Botucatu, 10 the standardization of conducts in this Manual led to the elaboration of a protocol in the form of flowchart that includes the evaluation of Nutritional Risk and Nutritional Therapy in patients undergoing HSCT. Conclusion: the risk assessment and nutrition therapy application protocols, built in the form of a flowchart, facilitate the applicability of the manual contents, simplify the classification of nutritional risk groups, provide rapid pipeline elaboration and avoid divergences of prescription regarding the best nutritional therapy in patients undergoing HSCT.
|
769 |
Protocolo para avaliação e terapia nutricional no transplante de células hematopoiéticas em pacientes do Hospital das Clínicas de BotucatuCosta, Cesar Martins da January 2018 (has links)
Orientador: Paula Schmidt Azevedo Gaiolla / Resumo: O Transplante de Células Progenitoras Hematopoiéticas (TCPH) é um método terapêutico utilizado no tratamento de diversas doenças que envolvem o tecido linfo-hematopoiético, doenças autoimunes e condições não-malignas. As evidências apontam que o reconhecimento precoce de pacientes em grupos de risco nutricional no TCPH e a elaboração de um plano terapêutico para tal tem impacto positivo na redução da mortalidade. A monitorização diária das necessidades energéticas, proteicas e de nutrientes é um dos pontos cruciais da terapia, pois o paciente que é incapaz de suprir mais do que 60% das necessidades nutricionais diárias por via oral torna-se candidato a outras modalidades de terapia (enteral ou parenteral), a depender da viabilidade do trato gastrointestinal, das contra-indicações relativas a cada método (plaquetopenia na introdução de sonda nasoenteral, por exemplo) e das complicações associadas aos procedimentos (aumento das taxas de infecção de corrente sanguínea na nutrição parenteral). Se o paciente atingir mais do que 60% das necessidades nutricionais por via oral e mantiver esse aporte por pelo menos 3 dias, o suporte por nutrição enteral ou parenteral pode ser descontinuado. A literatura científica ainda não elucidou todos os questionamentos quanto à melhor abordagem nutricional em pacientes submetidos a TCPH, podendo-se observar grande variação entre as condutas orientadas pelas diretrizes internacionais mais recentes e o que se adota como prática clínica diária, cham... (Resumo completo, clicar acesso eletrônico abaixo) / Abstract: Hematopoietic Stem Cell Transplantation (HSCT) is a therapeutic method used for treatment of various diseases involving lymphohematopoietic tissue, autoimmune diseases and non-malignant conditions. Evidence indicates that the early recognition of nutritional risk in HSCT patients and the elaboration of a therapeutic plan for them has a positive impact in reducing mortality. Monitoring daily needs of energy, protein and nutrient is one of the crucial points of therapy, because individuals who are unable to supply more than 60% of the daily nutritional needs orally become candidates for other modalities of therapy (enteral or parenteral), depending on the viability of the gastrointestinal tract, contraindications for each method (thrombocytopenia in the introduction of nasoenteral probe, for example) and complications associated with procedures (increased bloodstream infection rates in parenteral nutrition) . If the patient reaches more than 60% of nutritional needs orally and maintains this intake for at least 3 days, enteral or parenteral nutrition support may be discontinued. The scientific literature has not yet elucidated all the questions regarding the best nutritional approach in patients undergoing HSCT and a great variation between the conducts guided by the most recent international guidelines and what is adopted as daily clinical practice can be observed, drawing attention to the need for nutritional protocols that could reduce these divergences. Objectives: elabora... (Complete abstract click electronic access below) / Mestre
|
770 |
Aspirado de medula óssea e plasma rico em plaquetas, associados ou não à terapia com laser em baixa intensidade no reparo ósseo: estudo histomorfométrico e imunoistoquímico / Bone marrow aspirate and platelet-rich plasma combined or not with low-level laser therapy on bone healing: a histomorphometric and immunohistochemical studyBelem, Eduarda de Lima Graciano [UNESP] 26 August 2016 (has links)
Submitted by EDUARDA DE LIMA GRACIANO BELEM null (eduarda.belem@hotmail.com) on 2016-09-19T17:45:24Z
No. of bitstreams: 1
Dissertação - Eduarda de Lima Graciano Belem (19-09-16).pdf: 1696256 bytes, checksum: 5d66d1f4ebfc8533efcd6e4b3df8a441 (MD5) / Approved for entry into archive by Felipe Augusto Arakaki (arakaki@reitoria.unesp.br) on 2016-09-22T14:58:30Z (GMT) No. of bitstreams: 1
belem_elg_me_araca_par.pdf: 642200 bytes, checksum: cfac5618a8e05e501e2a63bd42199005 (MD5) / Made available in DSpace on 2016-09-22T14:58:30Z (GMT). No. of bitstreams: 1
belem_elg_me_araca_par.pdf: 642200 bytes, checksum: cfac5618a8e05e501e2a63bd42199005 (MD5)
Previous issue date: 2016-08-26 / Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) / Este estudo avaliou a influência do aspirado de medula óssea (AMO) e do plasma rico em plaquetas (PRP) associados ou não à terapia com laser em baixa intensidade (LLLT) no reparo ósseo de defeitos de tamanho crítico (DTC), criados cirurgicamente em calvárias de ratos. 96 ratos foram divididos em 6 grupos: C, PRP, AMO, LLLT, PRP/LLLT e AMO/LLLT. Um DTC de 5 mm de diâmetro foi criado na calvária de cada animal. No grupo C, o defeito foi preenchido com coágulo sanguíneo somente. Nos grupos PRP e AMO, o defeito foi preenchido com PRP e AMO, respectivamente. No grupo LLLT, o defeito recebeu aplicação da LLLT (InGaAlP), foi preenchido com coágulo sanguíneo e irradiado novamente. Nos grupos PRP/LLLT e AMO/LLLT, o defeito recebeu aplicação da LLLT, foi preenchido com PRP ou AMO, respectivamente e irradiado novamente. Os animais foram submetidos à eutanásia aos 10 ou 30 dias pós-operatórios. Foram realizadas análises histomorfométrica e imunoistoquímica. A área de osso neformado (AON) foi calculada como porcentagem da área total do defeito original. Foram realizadas reações imunoistoquímicas para detecção do antígeno nuclear de proliferação celular (PCNA), proteínas morfogenéticas ósseas 2/4 (BMP-2/4) e osteocalcina (OCN). As células PCNA-positivas, BMP-2/4-positivas e OCN-positivas foram quantificadas. Os dados foram analisados estatisticamente. Aos 10 dias pós-operatórios, o grupo AMO apresentou AON significativamente maior que o grupo C. Aos 30 dias pós-operatórios, o grupo AMO apresentou AON significativamente maior que os grupos C e LLLT, bem como números significativamente maiores de células BMP-2/4-positivas e OCN-positivas que o grupo C. Dentro dos limites deste estudo, pode-se concluir que a terapia com AMO promoveu a regeneração óssea em defeitos de tamanho crítico em calvárias de ratos, tanto aos 10 dias como aos 30 dias pós-operatórios. / This study evaluated the influence of bone marrow aspirate (BMA) and platelet-rich plasma (PRP) combined or not with low-level laser therapy (LLLT) on bone healing in surgically created critical-size defects (CSD) in rat calvaria. 96 rats were divided into 6 groups: C, PRP, BMA, LLLT, PRP/LLLT and BMA/LLLT. A 5 mm diameter CSD was created in the calvarium of each animal. In Group C, the defect was filled by blood clot only. In groups PRP and BMA, the defects were filled with PRP and BMA, respectively. In Group LLLT, the defect received laser irradiation (InGaAlP laser), was filled with blood clot and irradiated again. In groups PRP/LLLT and BMA/LLLT, the defect received laser irradiation (InGaAlP laser), was filled with PRP or BMA, respectively, and irradiated again. Animals were euthanized at either 10 or 30 days postoperative. Histomorphometric and immunohistochemical analyses were performed. Newly formed bone area (NFBA) was calculated as a percentage of the total area of the original defect. Proliferating cell nuclear antigen (PCNA), bone morphogenetic protein 2/4 (BMP-2/4) and osteocalcin (OCN) immunohistochemical staining were performed. PCNA-positive, BMP-2/4-positive and OCNpositive cells were quantified. Data were statistically analyzed. At 10 days postoperative, Group BMA presented significantly greater NFBA than control. At 30 days postoperative, Group BMA presented significantly greater NFBA than control and Group LLLT, as well as significantly higher numbers of BMP-2/4-positive and OCN-positive cells than control. Within the limits of this study, it can be concluded that the treatment with BMA promoted bone regeneration in critical-size rat calvarial defects at both 10 and 30 days postoperative. / FAPESP: 2014/02094-5
|
Page generated in 0.0529 seconds